Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 132Lymphoid 82Other hematologic neoplasm 23Myeloid 5Genitourinary 4Dermatologic 3Tumor-Agnostic 2Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1Anemia 1

Interventions

Epoetin Alfa 38Darbepoetin alfa 30epoetin beta 10Rivaroxaban 9olaparib 5eltrombopag 5apixaban 5Heparin, Low-Molecular-Weight 5pegylated granulocyte colony-stimulating factor 4pegfilgrastim 4emicizumab 4Gemcitabine 4Filgrastim 4Dalteparin 4Cyclophosphamide 4AP 1903 reagent 4romiplostim 3peginesatide 3luspatercept 3hetrombopag 3hematide 3Vancomycin 3ON 01910 3Enoxaparin 3Azacitidine 3ACE-011 3venetoclax 2telapristone acetate 2roxadustat 2iron isomaltoside 1000 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lenalidomide × Classical hematology × Clear all
NCT00179621 2011-04-14

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Celgene

Phase 3 Completed
205 enrolled 25 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡